Rongchang Biotech announced that the company previously signed a licensing agreement with Vor Bio on June 25, 2025 for taitacip. On November 12, 2026, the company signed a revised agreement with Vor Bio to include the self-developed RC298 in the scope of cooperation, granting Vor Bio the exclusive right to develop and commercialize in global regions other than Greater China. The company retains all of RC298's rights in Greater China. The company will receive a total down payment worth approximately $56 million, including $10 million in cash and share warrants to subscribe for 2.3 million shares of Vor Bio's common shares; it will also be eligible for development milestone payments of up to $300 million, of which $20 million will need to be obtained after reaching early clinical development and technology transfer milestones. Milestone payments are subject to certain conditions, and the final amount is uncertain. RC298 is currently in the pre-clinical development stage to prepare the IND declaration, and there is still uncertainty about clinical research results and final regulatory approval.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.